1 Global tuberculosis control: epidemiology, strategy, financing. WHO report 2009. Geneva, Switzerland: World Health Organization, 2009.
2 Parrish NM, Dick JD, Bishai WR.Mechanisms of latency in Mycobacterium tuberculosis. Trends Microbiol 1998; 6:107–12.
3 Tufariello J, Chan J, Flynn J. Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect Dis 2003; 3:578–90.
4 Kaufmann SH. How can immunology contribute to the control of tuberculosis? Nat Rev Immunol 2001; 1:20–30.
5 Nakaoka H, Lawson L, Squire SB et al. Risk for tuberculosis among children. Emerg Infect Dis 2006; 12:1383–8.
6 Khalilzadeh S, Masjedi H, Hosseini M, Safavi A, Masjedi MR. Transmission of Mycobacterium tuberculosis to households of tuberculosis patients: a comprehensive contact tracing study. Arch Iran Med 2006; 9:208–12.
7 Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010; (1):CD000171.
8 Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H, Centers for Disease Control and Prevention (CDC), National Institutes of Health, HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1–207.
9 Quigley MA, Mwinga A, Hosp M et al. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS 2001; 15:215–22.
10 Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis 2006; 12:744–51.
11 Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 2008; 8:533–44.
12 Krausgruber T, Blazek K, Smallie T et al. IRF5 promotes inflammatory macrophage polarization and TH1–TH17 responses. Nat Immunol 2011; 12:231–8.
13 Stanley E, Lieschke GJ, Grail D et al. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci USA 1994; 91:5592–6.
14 Rose RM, Kobzik L, Dushay K et al. The effect of aerosolized recombinant human granulocyte macrophage colony- stimulating factor on lung leukocytes in nonhuman primates. Am Rev Respir Dis 1992; 146:1279–86.
15 Wang J, Snider DP, Hewlett BR et al. Transgenic expression of granulocyte–macrophage colony-stimulating factor induces the differentiation and activation of a novel dendritic cell population in the lung. Blood 2000; 95:2337–45.
16 Miller G, Pillarisetty VG, Shah AB, Lahrs S, Xing Z, DeMatteo RP. Endogenous granulocyte–macrophage colony-stimulating factor overexpression in vivo results in the long-term recruitment of a distinct dendritic cell population with enhanced immunostimulatory function. J Immunol 2002; 169:2875–85.
17 García-Romo GS, Pedroza-González A, Aguilar-León D et al. Airways infection with virulent Mycobacterium tuberculosis delays the influx of dendritic cells and the expression of costimulatory molecules in mediastinal lymph nodes. Immunology 2004; 112:661–8.
18 Balboa L, Romero MM, Yokobori N et al. Mycobacterium tuberculosis impairs dendritic cell response by altering CD1b, DC-SIGN and MR profile. Immunol Cell Biol 2010; 88:716–26.
19 Hernández-Pando R, Orozco H, Sampieri A et al. Correlation between the kinetics of Th1/Th2 cells and pathology in a murine model of experimental pulmonary tuberculosis. Immunology 1996; 89:26–33.
20 Hernández-Pando R, Orozco EH, Arriaga AK, Sampieri A, Larriva-Sahd J, Madrid MV. Analysis of the local kinetics and localization of interleukin-1a, tumor necrosis factor-a and transforming growth factor-b, during the course of experimental pulmonary tuberculosis. Immunology 1997; 90:607–17.
21 Mata-Espinosa DA, Mendoza-Rodríguez V, Aguilar-León D, Rosales R, López-Casillas F, Hernández-Pando R. Therapeutic effect of recombinant adenovirus encoding interferon-gamma in a murine model of progressive pulmonary tuberculosis. Mol Ther 2008; 16:1065–72.
22 Arriaga AK, Orozco EH, Aguilar LD, Rook GA, Hernández-Pando R. Immunological and pathological comparative analysis between experimental latent tuberculous infection and progressive pulmonary tuberculosis. Clin Exp Immunol 2002; 128:229–37.
23 Marquina-Castillo B, García-García L, Ponce-de-León A et al. Virulence, immunopathology and transmissibility of selected strains of Mycobacterium tuberculosis in a murine model. Immunology 2009; 128:123–33.
24 Lifshitz L, Tabak G, Gassmann M, Mittelman M, Neumann D. Macrophages as novel target cells for erythropoietin. Haematologica 2010; 95:1823–31.
25 Ghosn EE, Cassado AA, Govoni GR et al. Two physically, functionally, and developmentally distinct peritoneal macrophage subsets. Proc Natl Acad Sci USA 2010; 107:2568–73.
26 Egen JG, Rothfuchs AG, Feng CG,Winter N, Sher A, Germain RN. Macrophage and T cell dynamics during the development and disintegration of mycobacterial granulomas. Immunity 2008; 28:271–84.
27 Cooper AM, Flynn JL. The protective immune response to Mycobacterium tuberculosis. Curr Opin Immunol 1995; 7:512–6.
28 Burgess AW, Camakaris J, Metcalf D. Purification and properties of colony-stimulating factor from mouse lung-conditioned medium. J Biol Chem 1977; 252:1998–2003.
29 Frossard JL, Saluja AK, Mach N et al. In vivo evidence for the role of GM-CSF as a mediator in acute pancreatitis-associated lung injury. Am J Physiol Lung Cell Mol Physiol 2002; 283:L541–548.
30 Wada H, Noguchi Y, Marino MW, Dunn AR, Old LJ. T cell functions in granulocyte/macrophage colony-stimulating factor deficient mice. Proc Natl Acad Sci USA 1997; 94:12557–61.
31 Gonzalez-Juarrero M, Hattle JM, Izzo A et al. Disruption of granulocyte macrophage-colony stimulating factor production in the lungs severely affects the ability of mice to control Mycobacterium tuberculosis infection. J Leukoc Biol 2005; 77:914–22.
32 Griffin JD, Cannistra SA, Sullivan R, Demetri GD, Ernst TJ, Kanakura Y. The biology of GM-CSF: regulation of production and
interaction with its receptor. Int J Cell Cloning 1990; 8 (Suppl.1):35–44.
33 Huleihel M, Douvdevani A, Segal S, Apte RN. Different regulatory levels are involved in the generation of hemopoietic cytokines (CSFs and IL-6) in fibroblasts stimulated by inflammatory products. Cytokine 1993; 5:47–56.
34 Shi Y, Liu C, Roberts A et al. Garnulocyte–macrophage colonystimulating factor and T cell responses; what we do and don’t
know. Cell Res 2006; 16:126–33.
35 Sagawa K, Mochizuki M, Sugita S, Nagai K, Sudo T, Itoh K. Suppression by IL-10 and IL-4 of cytokine production induced by
two-way autologous mixed lymphocyte reaction. Cytokine 1996;8:501–6.
36 Adcock IM, Caramori G. Cross-talk between pro-inflammatory transcription factors and glucocorticoids. Immunol Cell Biol
2001; 79:376–84.
37 Condos R, Rom WH, Schluger NW. Treatment of multidrug resistant pulmonary TB with interferon-gamma via aerosol. Lancet 1997; 349:1513–5.
38 Giosué S, Casarini M, Alemanno L et al. Effects of aerosolized interferon-alpha in patients with pulmonary TB. Am J Respir Crit Care Med 1998; 158:1156–62.
39 Roediger EK, Kugathasan K, Zhang X, Lichty BD, Xing Z. Heterologous boosting of recombinant adenoviral prime immunization with a novel vesicular stomatitis virus-vectored tuberculosis vaccine. Mol Ther 2008; 16:1161–9.
40 Ryan AA, Wozniak TM, Shklovskaya E et al. Improved protection against disseminated tuberculosis by Mycobacterium bovis bacillus Calmette–Guérin secreting murine GM-CSF is associated with expansion and activation of APCs. J Immunol 2007; 179:18–
24.
41 Nambiar JK, Ryan AA, Kong CU, Britton WJ, Triccas JA. Modulation of pulmonary DC function by vaccine-encoded GM-CSF enhances protective immunity against Mycobacterium tuberculosis infection. Eur J Immunol 2010; 40:153–61.
42 Zhang X, Divangahi M, Ngai P et al. Intramuscular immunization with a monogenic plasmid DNA tuberculosis vaccine: enhanced immunogenicity by electroporation and co-expression of GMCSF transgene. Vaccine 2007; 25:1342–52.
43 Quezada G, Koshkina NV, Zweidler-McKay P, Zhou Z, Kontoyiannis DP, Kleinerman ES. Intranasal granulocyte–macrophage colony-stimulating factor reduces the Aspergillus burden in an immunosuppressed murine model of pulmonary aspergillosis. Antimicrob Agents Chemother 2008; 52:716–8.
44 Lu H, Xing Z, Brunham RC. GM-CSF transgene-based adjuvant allows the establishment of protective mucosal immunity following vaccination with inactivated Chlamydia trachomatis. J Immunol 2002; 169:6324–31.
45 Steinwede K, Tempelhof O, Bolte K et al. Local delivery of GM-CSF protects mice from lethal pneumococcal pneumonia. J Immunol 2011; 187:5346–56.
46 Tazawa R, Trapnell BC, Inoue Y et al. Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2010; 181:1345–54.
47 Lei XF, Ohkawara Y, Stämpfli MR et al. Compartmentalized transgene expression of granulocyte–macrophage colony-stimulating factor (GM-CSF) in mouse lung enhances allergic airways inflammation. Clin Exp Immunol 1998; 113:157–65.
48 Lang RA, Metcalf D, Cuthbertson RA et al. Transgenic mice expressing a hemopoietic growth factor gene (GM-CSF) develop accumulations of macrophages, blindness, and a fatal syndrome of tissue damage. Cell 1987; 51:675–86.
49 Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345:1098–104.
50 McClure J, van’t Wout AB, Tran T et al. Granulocyte–monocyte colony-stimulating factor upregulates HIV-1 replication in monocyte-derived macrophages cultured at low density. J Acquir Immune Defic Syndr 2007; 44:254–61.